Objectives: A 25-yr-old man from Prague had abnormal bleeding after several surgical operations with low fibrinogen level and hypofibrinogenemia was suspected.
Patients And Methods: The patient, 25 yr-old male had a low fibrinogen concentration as determined by the thrombin time and immunoturbidimetrical method. His 48-yr-old mother presented with normal coagulation tests, normal fibrinogen level and reported no history of bleeding. To identify the genetic mutation responsible for this hypofibrinogen, genomic DNA extracted from the blood was analyzed. Fibrin polymerization measurement, kinetics of fibrinopeptide release, fibrinogen clottability measurement, mass spectroscopy, and scanning electron microscopy were performed.
Results: DNA sequencing showed heterogeneous fibrinogen gammaG351S mutation in the propositus. The mutant chain was found not to be expressed to the circulation by matrix-assisted laser desorption/ionization time of flight mass spectrometry. Scanning electron micrographs of the patient's fibrin clot as well as kinetics of fibrinopeptide release and fibrin polymerization were found to be normal.
Conclusion: A case of hypofibrinogenemia gammaG351S was found by routine coagulation testing and was genetically identified.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0609.2007.00838.x | DOI Listing |
Clin Appl Thromb Hemost
January 2025
Department of Rheumatology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan Province Clinical Research Center for Hematologic Disease, Kunming, Yunnan, China.
Objectives: To explore the risk factors for thrombi occurring in patients with immune thrombocytopenia (ITP) and establish a risk prediction model to better predict the risk of thrombosis in patients with ITP.
Methods: We retrospectively analyzed 350 ITP patients who had been hospitalized in the First People's Hospital of Yunnan Province between January 2024 and June 2024. For all patients, we recorded demographic characteristics and clinical data, analyzed the risk factors for thrombosis in ITP patients and then developed a risk prediction model.
ACS Omega
December 2024
Department of Biochemistry, Federal University of São Paulo, São Paulo, SP 04044-020, Brazil.
J Thromb Haemost
January 2025
Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.
Background: Blood clot formation, triggered by vascular injury, is crucial for haemostasis and thrombosis. Blood clots are composed mainly of fibrin fibres, platelets and red blood cells (RBCs). Recent studies show that clot surface also develops a fibrin film, which provides protection against wound infection and retains components such as RBCs within the clot.
View Article and Find Full Text PDFCureus
December 2024
Department of General Medicine, Father Muller Medical College, Bangalore, IND.
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that imposes significant complications, including diabetic peripheral neuropathy (DPN). DPN is characterized by marked inflammation, and the fibrinogen-to-albumin ratio (FAR) is one of the new markers for systemic inflammation, it has been used in various diabetic micro- and macro-vascular complications. The present study investigates the association between FAR and nerve conduction abnormalities in T2DM patients with DPN.
View Article and Find Full Text PDFJ Cardiothorac Surg
December 2024
Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beilishi Road No. 167, Xicheng District, Beijing, 100037, China.
Background: Little is known about the role of D-dimer (DD) on the prognosis of patients undergoing coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG).
Methods: A total of 371 patients undergoing CE with CABG between January 2018 and July 2022 were retrospectively enrolled. The primary endpoint was the perioperative major adverse cardiovascular and cerebrovascular events (MACCE).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!